Basilea Pharmaceutica AG (SWX:BSLN)
Switzerland · Delayed Price · Currency is CHF 66.70
+2.20 (3.41%)
Sep 11, 2026, 5:30 PM CET
Basilea Pharmaceutica AG Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Basilea Pharmaceutica AG stock has a consensus rating of "Buy" and an average price target of CHF 105.37. The average 1-year stock price forecast is 57.98% higher than the current stock price, while the lowest is CHF 70.00 (+4.95%) and the highest is CHF 126.10 (+89.06%).
Price Target: CHF 105.37 (+57.98%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on Apr 13, 2026.
Analyst Ratings
The average analyst rating for Basilea Pharmaceutica AG stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Kepler Capital | Kepler Capital | Buy Maintains CHF 69.00 → CHF 70.00 | Buy | Maintains | CHF 69.00 → CHF 70.00 | +4.95% | Apr 13, 2026 |
Financial Forecast
Revenue This Year
267.25M
from 232.38M
Increased by 15.00%
Revenue Next Year
274.62M
from 267.25M
Increased by 2.76%
EPS This Year
4.18
from 3.14
Increased by 32.98%
EPS Next Year
4.56
from 4.18
Increased by 9.18%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CHF.